Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination S100A1 and ARC gene therapy as a treatment for DMD cardiomyopathy.

JCI insight·2026
Same author

Effects of Age on Intervertebral Disc Tissue Morphology and Gene Expression in the ADAM8-Inactivation Mouse.

Cells·2026
Same author

Fish and Zooplankton Co-Responses to Environmental Gradients Under Different Climate Change Scenarios.

Global change biology·2026
Same author

Targeted LNP-mediated delivery of VE-cadherin mRNA reduces vascular hyperpermeability in vivo.

Blood advances·2026
Same author

Direct Observation of Nanometer-Sized Steps of Single Myosin VI Molecules in Living Cells.

Nano letters·2026
Same author

Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophy.

Skeletal muscle·2026

Related Experiment Video

Updated: Jun 8, 2026

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

Leupeptin-based inhibitors do not improve the mdx phenotype.

Joshua Selsby1, Klara Pendrak, Monica Zadel

  • 1Department of Physiology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|September 17, 2010
PubMed
Summary

Pharmacological calpain inhibition did not improve outcomes in Duchenne muscular dystrophy models. Skeletal muscle countered these inhibitors by increasing degradative pathways, suggesting this approach is not a viable therapeutic strategy.

More Related Videos

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

Related Experiment Videos

Last Updated: Jun 8, 2026

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Muscle Physiology

Background:

  • Calpain activation is linked to Duchenne muscular dystrophy (DMD) pathology.
  • Calpain inhibition is a potential therapeutic strategy for DMD, aiming to reduce protein degradation and fibrosis.
  • Conflicting reports exist regarding the role of calpastatin, an endogenous calpain inhibitor, in DMD.

Purpose of the Study:

  • To investigate the efficacy of pharmacological calpain inhibition in the mdx mouse model of DMD.
  • To compare the effects of leupeptin and a novel compound (C101) on muscle pathology, function, and biochemical markers in mdx mice.

Main Methods:

  • Administration of leupeptin and C101 to mdx mice.
  • Assessment of muscle histology, function, and serum creatine kinase levels.
  • Biochemical analysis of calpain activity, autolysis, proteasome activity, and calpastatin levels.

Main Results:

  • Neither C101 (4 weeks) nor leupeptin (6 months) improved muscle histology, function, or creatine kinase levels in mdx mice.
  • Leupeptin administration increased m-calpain autolysis and proteasome activity.
  • Calpastatin levels remained unchanged in treated versus untreated mdx mice.

Conclusions:

  • Pharmacological calpain inhibition is not a promising therapeutic intervention for Duchenne muscular dystrophy.
  • Skeletal muscle can counteract calpain inhibitors by upregulating alternative degradative pathways, limiting therapeutic efficacy.